Categories: CancerNews

iCAD to Report Second Quarter 2022 Financial Results on August 10, 2022

NASHUA, N.H., July 27, 2022 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the second quarter ended June 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on August 10, 2022.

August 10, 2022 at 4:30 PM ET
Domestic: 888-506-0062                
International: 973-528-0011                
Conference ID: 718241        
Webcast: https://www.webcaster4.com/Webcast/Page/2879/46166                

About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.

Contact:
Media Inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com 

Investor Inquiries:
iCAD Investor Relations
ir@icadmed.com 

Staff

Recent Posts

Eleos Expands Executive Leadership Bench Following Series C Fundraise

Additional Hiring and Product Expansions Planned Through 2025BOSTON and TEL AVIV, Israel, April 10, 2025…

40 minutes ago

Elixir Medical Announces Launch of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe

Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary…

40 minutes ago

New York Plastic Surgical Group and Deep Blue Med Spa Receive State and National Recognition by Allergan Aesthetics

Allergan Aesthetics Top 25 York Plastic Surgical Group and Deep Blue Med Spa have been…

40 minutes ago

Over 53 Million Myeloma Milestones Shared During 2025 Myeloma Action Month

Myeloma Action Month Global Campaign Celebrates Resilience, Strengthens Connections, and Inspires Hope in 52 Countries…

40 minutes ago

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Industry leader in the development and application of cellular therapies, including CAR NK products, for…

40 minutes ago

Cuprina Holdings (Cayman) Limited Announces Pricing of $12 million Initial Public Offering

SINGAPORE, April 10, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (“CUPR” or “the Company”),…

41 minutes ago